ClinicalTrials.gg
WithdrawnNCT04106076Updated Jul 14, 2020

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

A Phase 1 interventional study of UCART123 in Acute Myeloid Leukaemia, sponsored by Cellectis S.A.. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-14.

Sponsored by Cellectis S.A. · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
The trial was discontinued due to sponsor's decision and not a consequence of any safety concern

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).

02

Conditions studied

  • Acute Myeloid Leukaemia

Keywords

  • Acute Myeloid Leukaemia
  • Newly diagnosed AML
  • ELN adverse genetic risk group
  • Chimeric Antigen Receptor T-Cell (CAR-T) therapy
  • Allogeneic
  • Transcription Activator-Like Effector Nuclease (TALEN)
03

In context

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Cellectis S.A. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined as per ELN guidelines (Döhner et al., 2017)
  • performance status of 0 or 1
  • No prior gene or experimental cellular therapy
  • No organ dysfunction that in the opinion of the investigator precludes intensive induction chemotherapy or cellular therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.

    Biological: UCART123

Interventions

  • BiologicalUCART123

    Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor

06

What researchers measure

Primary outcomes

  1. Incidence of AE/SAE/DLT [Safety and Tolerability]

    Incidence, nature, and severity of adverse events and serious adverse events (SAEs) throughout the study

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Dec 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Sep 26, 2019
StartActual
Jul 11, 2019
Primary completionActual
Dec 5, 2019
CompletionActual
Dec 5, 2019
Last update
Jul 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04106076
Lead sponsor
Cellectis S.A.
Responsible party
Sponsor
First posted
Sep 26, 2019
Start date
Jul 11, 2019
Primary completion
Dec 5, 2019
Completion
Dec 5, 2019
Last update
Jul 14, 2020

Study contacts

Ghulam Mufti, Pr
principal investigator · Kings college London NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion